Intra-Cellular Therapies, Phase 2 clinical study using its drug candidate ITI-722 for sleep maintenance insomnia

DECEMBER 20TH, 2007 -- Intra-Cellular Therapies, Inc. (ITI), announced it has initiated a sleep maintenance insomnia (SMI) Phase 2 clinical study using its drug candidate ITI-722. ITI-722 acts predominantly as a selective 5-HT2A receptor antagonist and represents an important new approach to the treatment of SMI. Because of its novel separation of 5-HT2A and dopamine receptor modulatory activities, ITI believes, ITI-722 can be used not only to treat SMI but it may be highly appropriate for the treatment of sleep disorders that accompany neurodegenerative disorders, including Parkinson’s disease and other psychiatric disorders... Intra-Cellular Therapies' Press Release -

Actelion, Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant)

20 December 2007 – Actelion Ltd (SWX: ATLN) announced that the company has initiated the comprehensive Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant) with its first-in-class orexin receptor antagonist, almorexant...RESTORA 1 is expected to confirm the effects of almorexant on sleep induction and sleep maintenance that were previously observed. This study is also expected to provide additional information on sleep architecture and sleep quality, thereby providing further insight into the role of almorexant in restoring normal physiological sleep... Actelion's Press Release -

Embla Systems, to develop Cardio-Pulmonary Coupling Technology

Dec. 13 , 2007- Embla Systems, a leader in the field ofsleep diagnostic software and equipment announced today the signing of an exclusive agreement with the Beth Israel Deaconess Medical Center (BIDMC) for the distribution of the Cardio Pulmonary Coupling (CPC) technology developed by Drs. Robert Thomas, Ary Goldberger, C-K. Peng, and Mr. Joseph Mietus... The CPC technology will give physicians the "Sleep Health" of a patient and to evaluate if the patient has Obstructive, Central or Complex Sleep Apnea ... [PDF] Embla's Press Release -

UCB's Neupro, Filed with the FDA for the Treatment of Restless Legs Syndrome

December 12, 2007 - UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA)...Restless Legs Syndrome is a chronic neurological disorder that affects between three and ten per cent of the population...Symptoms of RLS typically appear during periods of rest and inactivity, particularly in the evenings and at night. This can make it difficult to fall asleep and stay asleep, thus preventing recuperative sleep and often leading to daytime fatigue and reduced alertness... UCB's Press Release -

CHAD's Sleep Product Opportunity

November 19, 2007 - ... Targeted for use in sleep laboratories, CHAD believes that its FloChannel^TM sleep diagnostic device is the only device that can independently monitor left and right nasal airflow, oral airflow and snoring. The device is designed to provide constant baseline airflow volumetric sleep scoring and to evaluate the effects of nasal resistance and nasal cycling. "CHAD believes these features should provide a competitive advantage over products currently in the market, which treat the nasal passages as one airway when in fact they are two airways... Chad's Press Release by BW -

MediciNova , Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia

Oct 18, 2007 - MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), announced results from a Phase IIa clinical study of MN-305, its product candidate for the treatment of insomnia. The clinical study failed to achieve statistical significance in its primary endpoint of reducing Wake (time) After Sleep Onset (WASO). MN-305 was well tolerated in this study with no clinically significant adverse events observed at any dose tested... MediciNova's Press Release-

Immtech , Interim Analysis in Phase III African Sleeping Sickness Trial

Thursday October 4, 2007 - Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness*... Immtech's Press Release [PDF]-

Upstream Biosciences, New Approach to Treating Sleeping Sickness

October 2, 2007 - Upstream Biosciences Inc. (OTCBB: UPBS) announced that its Chief Executive Officer, Joel L. Bellenson, will unveil Upstream's promising new drug candidates in a keynote address to the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) conference being held in Angola from October 1 to 5, 2007... Trypanosomiasis is the medical term for the disease known as African sleeping sickness.... Upstream recently acquired access to innovative drug candidates designed to treat tropical parasitic diseases. In laboratory studies in vitro, these compounds have demonstrated human and veterinary potential against several major tropical parasitic diseases, including trypanosomiasis... Upstream Biosciences' Press Release -

Transcept Pharmaceuticals, Middle-of-the-Night (MOTN) Insomnia

October 1, 2007: Transcept Pharmaceuticals, Inc. announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia ( form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep) at the Natixis Bleichroeder “Hidden Gems” Healthcare Conference... Transcept's Press Release -

Arena Pharmaceuticals, Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia

Sept. 25, 2007 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive preliminary results from its Phase 2 clinical trial of APD125 in patients with chronic insomnia. APD125 is an orally available drug candidate discovered by Arena that is being evaluated in insomnia patients who have difficulty maintaining sleep after initial sleep onset... Arena's Press Release -

Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness

Sept. 19, 2007- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis (HAT), also known as African sleeping sickness... Immtech Pharmaceuticals' Press Release [PDF] -

Efficacy and Benefit of Restore Medical's Pillar(R) Procedure

Sept. 18, 2007--Restore Medical, Inc. (NASDAQ:REST), developer of the innovative Pillar(R) Palatal Implant System - a simple, minimally-invasive treatment to help individuals suffering from snoring and mild-to-moderate obstructive sleep apnea (OSA) - today announced the presentation of positive results from the first U.S. multi-center Level 1 evidence based medicine clinical study of its Pillar palatal implants, which affirmed the efficacy observed in earlier studies in the treatment of mild to moderate OSA... Restore Medica's Press Procedure -

Neurogen , Webcast of Insomnia Focus

Sept. 18, 2007--Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced the webcast of its Insomnia Focus Investor meeting on September 25, 2007, from 11:45 a.m. to 2:00 p.m. ET.

Neurogen and guest speakers will take an in-depth look at insomnia therapeutics on the market and in development, and the role of NRGN's adipiplon (formerly NG2-73) in this changing marketplace. Guest speakers are... Neurogen's Press Release -

Cephalon, PROVIGIL Label Updates

Sept. 17, 2007 - Cephalon, Inc. (Nasdaq: CEPH) announced that it has finalized and shared with healthcare professionals revisions to the label for PROVIGIL(R) (modafinil) Tablets [C-IV], its wake-promoting agent... PROVIGIL and NUVIGIL each are indicated to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), shift work sleep disorder and narcolepsy... Cephalon's Press Release -

Restore Medical, Clinical Study to Evaluate Pillar Palatal Implants in Combination with Continuous Positive Airway Pressure

Sept. 17, 2007--Restore Medical, Inc. (NASDAQ:REST), developer of the innovative Pillar(R) Palatal Implant System - a simple, minimally-invasive treatment to help individuals suffering from snoring and mild-to-moderate obstructive sleep apnea (OSA) - announced enrollment of the first patients in a clinical study evaluating the use of Pillar palatal implants in combination with continuous positive airway pressure (CPAP) therapy in the treatment of mild to moderate OSA... Restore Medical's Press Release -

SleePosition, blog about sleep disorders and treatments

The aim of the Blog "SleePosition" is to share information found in life sciences companies websites which could be interesting to follow new medical devices, pharmaceuticals, treatments, clinical trials for sleep disorders.